Anti-PD-L1 Antibodies
AssigneeAgency for Science, Technology and Research
InventorsCheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
Life of this patent
Estimating the term…
Abstract
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.
Claims17
1-31. (canceled)
An antibody, or antigen binding fragment, which is capable of binding to PD-L1, optionally isolated, having at least one light chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 18)
- LC-CDR1:
- TGSSSNIGAGYDVH
- (SEQ ID NO:
- 19)
- LC-CDR2:
- GNSNRPS
- (SEQ ID NO:
- 20)
- LC-CDR3:
- QSYDSSLSGSYVV;
- and
- having at least one heavy chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 21)
- HC-CDR1:
- SYAIS
- (SEQ ID NO:
- 22)
- HC-CDR2:
- RIIPILGIANYAQKFQG
- (SEQ ID NO:
- 25)
- HC-CDR3:
- SGHGYSYGAFDY.
A method of treating a T-cell dysfunctional disorder, cancer or an infectious disease, comprising administering an antibody or antigen binding fragment to a patient suffering from a T-cell dysfunctional disorder, cancer or an infectious disease, wherein antibody, or antigen binding fragment, is capable of binding to PD-L1, and comprises:
- at least one light chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 18)
- LC-CDR1:
- TGSSSNIGAGYDVH
- (SEQ ID NO:
- 19)
- LC-CDR2:
- GNSNRPS
- (SEQ ID NO:
- 20)
- LC-CDR3:
- QSYDSSLSGSYVV;
- and
- at least one heavy chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 21)
- HC-CDR1:
- SYAIS
- (SEQ ID NO:
- 22)
- HC-CDR2:
- RIIPILGIANYAQKFQG
- (SEQ ID NO:
- 25)
- HC-CDR3:
- SGHGYSYGAFDY.
A method for expanding a population of T cells, wherein T cells are contacted in vitro or ex vivo with an antibody or antigen binding fragment, wherein antibody, or antigen binding fragment, is capable of binding to PD-L1, and comprises:
- at least one light chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 18)
- LC-CDR1:
- TGSSSNIGAGYDVH
- (SEQ ID NO:
- 19)
- LC-CDR2:
- GNSNRPS
- (SEQ ID NO:
- 20)
- LC-CDR3:
- QSYDSSLSGSYVV;
- and
- at least one heavy chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 21)
- HC-CDR1:
- SYAIS
- (SEQ ID NO:
- 22)
- HC-CDR2:
- RIIPILGIANYAQKFQG
- (SEQ ID NO:
- 25)
- HC-CDR3:
- SGHGYSYGAFDY.
Dependencies are inferred from the claim text.